Vor Ort
Merkzettel Warenkorb
  • Produktbild: Cardiac Arrhythmias: New Therapeutic Drugs and Devices
  • Produktbild: Cardiac Arrhythmias: New Therapeutic Drugs and Devices
Band 47

Cardiac Arrhythmias: New Therapeutic Drugs and Devices Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA October 4 and 5, 1984

Aus der Reihe Developments in Cardiovascular Medicine

148,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

02.10.2011

Herausgeber

J. Morganroth + weitere

Verlag

Springer Us

Seitenzahl

356

Maße (L/B/H)

23,5/15,5/2,1 cm

Gewicht

563 g

Auflage

Softcover reprint of the original 1st ed. 1985

Sprache

Englisch

ISBN

978-1-4612-9626-3

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

02.10.2011

Herausgeber

Verlag

Springer Us

Seitenzahl

356

Maße (L/B/H)

23,5/15,5/2,1 cm

Gewicht

563 g

Auflage

Softcover reprint of the original 1st ed. 1985

Sprache

Englisch

ISBN

978-1-4612-9626-3

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Cardiac Arrhythmias: New Therapeutic Drugs and Devices
  • Produktbild: Cardiac Arrhythmias: New Therapeutic Drugs and Devices
  • I Basic Considerations.- 1 What animal models are useful in selecting new antiarrhythmic drugs?.- 2 How to test for antiarrhythmic drugs.- 3 Initial evaluation of new antiarrhythmic agents in man: normal volunteers or patients?.- 4 Is there a rational basis for the modified classification of antiarrhythmic drugs?.- Panel Discussion: Basic considerations.- II Status of Specific Antiarrhythmic Agents.- 5 Procainamide, Quinidine, Disopyramide, Cibenzoline, Pirmenol — efficacy in the treatment of ventricular arrhythmias: current status and controversies.- 6 Mexiletine, Tocainide and Ethmozine: newer class I antiarrhythmic agents.- 7 Class IC antiarrhythmic agents: status — 1984.- 8 Role of beta-blocking agents in the treatment of ventricular arrhythmias.- 9 Status of class III antiarrhythmic drugs: Amiodarone, Bretylium and Sotalol.- Panel Discussion: Status of specific antiarrhythmic agents.- III Special Considerations and FDA Standards.- 10 Some thoughts on efficacy trials of antiarrhythmic agents: pitfalls of mimicking clinical practice.- 11 Use of a computer in the new drug evaluation process.- 12 Sudden cardiac death — failure or effect of antiarrhythmic drug therapy?.- 13 Sudden death as an end-point for the clinical evaluation of antiarrhythmic drugs.- 14 Holter/exercise and electrophysiologic methods forevaluating drug therapy for malignant ventricular arrhythmias: do we need both models?.- Panel Discussion: Special considerations and FDA standards.- IV New Antiarrhythmic Devices.- 15 DVI vs DDD pacemakers - proarrhythmic or antiarrhythmic?.- 16 Pacing for ventricular tachycardia.- 17 Termination of ventricular tachycardia by transvenous cardioversion.- 18 The automatic implantable cardioverter/defibrillator.- 19 New antiarrhythmia devices — FDA’s requirements for effectiveness.- Panel Discussion: New antiarrhythmic devices.- V Evaluation Of Atrial Arrhythmias.- 20 Study designs to evaluate atrial arrhythmias are easy.- 21 Role of the autonomic nervous system in the generation of supraventricular tachyarrhythmias: clues to drug selection.- 22 Approaches to drug selection and serial drug testing.- Panel Discussion: Evaluation of atrial arrhythmias.- Participants.